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p53 regulates various cellular responses through transcriptional regulation of distinct sets of target
genes. Dual speciﬁcity phosphatase 6 (DUSP6) is a cytosolic phosphatase that inactivates the extra-
cellular-signal-regulated kinase 1/2 (ERK1/2). This study demonstrates that p53 transactivates
DUSP6 in human colorectal HCT116 cells to regulate ERK1/2 in p53-mediated cell death. DUSP6 is
transactivated by p53 overexpression and genotoxic agents, and chromatin immunoprecipitation
revealed two p53-binding sites in the DUSP6 promoter responsible for DUSP6 induction. Expression
of shDUSP6 inhibited 50-FU-induced cell death, whereas overexpression of DUSP6 increased suscep-
tibility to 50-FU. 50-FU treatment dephosphorylated ERK in a DUSP6-dependent manner, resulting in
destabilization of Bcl-2 and stabilization of Bad. These results provide insights on the modulatory
role of p53 in the survival pathway by up-regulating DUSP6.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The p53 tumor suppressor plays a key role in the regulation of
the cell cycle, DNA repair [1] and apoptosis [2]. Its activity is
mainly mediated through its role as a transcription factor that acti-
vates or inhibits the transcription of the target genes [3]. Identiﬁ-
cation of the p53 target genes that are involved in cell death or
the regulation of cell survival is necessary to deﬁne the molecular
mechanism(s) by which p53 functions as a tumor suppressor un-
der various cellular stresses.
Dual speciﬁcity phosphatase 6 (DUSP6) is one member of the
family of mitogen-activated protein kinase (MAPK) phosphatases
(MKPs) or cysteine-dependent DUSPs comprised of 10 catalytically
active proteins that share a common structure at their C-terminal
catalytic domain. DUSP6 speciﬁcally dephosphorylates extracellu-
lar-signal-regulated kinase (ERK), which distinguishes it from
other MAPK phosphatases such as DUSP1 and DUSP4, whichchemical Societies. Published by E
Biochemistry and Molecular
rsity School of Medicine, 309
c of Korea. Fax: +82 62 226
.
MD Anderson Cancer Center,instead exhibit broad substrate speciﬁcities for c-Jun N-terminal
kinase (JNK), p38, and ERK [4,5].
DUSP6 is a negative regulator of ERK stimulated with ﬁbroblast
growth factor (FGF) during mouse development [6]. Since ERK is a
key effector MAPK involved in the RAS-GTP signaling pathway in
response to signals from growth factor-receptor tyrosine kinase,
the regulation of ERK by DUSP6 could be crucial for deactivating
the survival signals stimulated by growth factors and determining
the cell fate in physiological conditions [7,8]. Therefore, inactiva-
tion of DUSP6 may abrogate the negative controlling pathway of
ERK and, subsequently, uncontrolled cell growth, which in turn
could lead to tumorigenesis and progression. Such cases have been
reported in pancreatic cancer cells, which show the gain-of-func-
tion mutations in the K-RAS2 gene [9,10]. DUSP6 expression was
signiﬁcantly decreased in the invasive carcinoma cells with pan-
creatic invasive carcinomas [11], in primary lung cancers [12],
and in ovarian cancers [13]. Furthermore, restoration of DUSP6
expression suppresses cellular proliferation in lung cancer cells
[12] and in ovarian cancer cells [13], impairs epithelial to mesen-
chymal transition and cell invasion in esophageal squamous cell
carcinoma cells [14], and sensitizes ovarian cancer cells to cis-
platin-induced apoptosis [13]. However, these tumor suppressive
roles of DUSP6 are complicated by observation that DUSP6 expres-
sion levels were increased in other tumors like melanoma [15],
breast cancers [16], and glioma [17]. These contradictory roles of
DUSP6 in tumorigenesis are not clearly understood yet.lsevier B.V. All rights reserved.
Table 1
List of primers.
Primer names Sequences
DUSP6-RT CGAGTCTGACCTTGACCGA
AGGCATCGTTCATCGACAG
GAPDH-RT CCATCACCATCTTCCAGGAGCGAG
TGCCAGTGAGCTTCCCGTTCAGCTC
p21-RT CGACTGTGATGCGCTAAT
CTTGGAGAAGATCAGCCG
p53-RT GTGCCTTCCCAGAAAACCTA
TCCGTGCCAGTAGATTACCA
shDUSP6 GATCCCCAAGACGGTGGCGTGGCTCAACTTCAAGAGAGTTG
AGCCACGCCACCGTCTTTTTTTGGAAAT
CGATTTCCAAAAAAAGACGGTGGCGTGGCTCAACTCTCTTGA
AGTTGAGCCACGCCACCGTCTTGGG
DUSP6 ChIP 1 GCGCTGGACAAAGGGAGGA
(1625 to 1425) TGAGCGAGGTGTGCTGGGA
4234 S. Piya et al. / FEBS Letters 586 (2012) 4233–4240Besides roles of DUSP6 in tumorigenesis, several reports
showed that DUSP6 inﬂuences cell death by regulating ERK activ-
ity. For instance, ERK1/2 phosphorylates Bad, a pro-apoptotic Blc-
2 family protein that disrupts the interaction with Bcl-xL, protect-
ing cells from apoptosis. However, DUSP6 inactivates ERK1/2 such
that unphosphorylated Bad can associate with Bcl-xL, leading to the
cell death [18]. Also, ERK1/2 can phosphorylate Bcl-2, and the
phosphorylated Bcl-2 protein is resistant to proteosomal degrada-
tion, protecting cells from apoptosis [19]. This protection can be
inhibited by DUSP6 expression through the inactivation of ERK1/2.
Here, we explored the potential p53 target genes that are asso-
ciated with cell death, and found that DUSP6 is a novel target gene
of p53, promoting the cell death in response to genotoxic stresses
by modulating ERK phosphorylation and the expression levels of
Bcl-2 family proteins such as Bad, Bcl-2 and Bcl-xL.DUSP6 ChIP 2 AGCCTACATTTCCCAAACCAGGGA
(2404 to 2125) TAATCCGGCCTTCCCTCCCTAAA2. Materials and methods
2.1. Cell culture and reagents
HCT116 human colorectal carcinoma parental cells and p53-
deﬁcient cells were maintained in McCoy’s 5A medium with 10%
fetal bovine serum (FBS) supplemented with 2 mM L-glutamate,
100 U/mL Penicillin and 100 lg/mL Streptomycin at 37 C in a
humidiﬁed atmosphere of 5% CO2. Recombinant human tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL) was gen-
erated as described previously [20]. 5-Flurouracil (5-FU) and Eto-
poside were purchased from Sigma–Aldrich (St. Louis, MO, USA).
Blasticidin was purchased from Invitrogen Life Technologies
(Valencia, CA, USA). Anti-actin antibody was purchased from
Chemicon International (Temacula, CA, USA). Anti-DUSP6 antibody
was purchased from Abnova (Taipei, Taiwan). Anti-p53 antibody
was purchased from Oncogene Science (Cambridge, MA, USA).
Anti-p21 antibody was purchased from BD Biosciences (Franklin
Lakes, NJ, USA). Anti-pERK1/2 and total anti-ERK antibody was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Horseradish peroxidase (HRP)-conjugated goat anti-rabbit/-mouse
IgGs were purchased from Jackson ImmunoResearch Lab (West
Grove, PA, USA).
2.2. Infection of adenovirus
HCT116 p53/ cells were infected with the recombinant aden-
oviral vector expressing wild-type p53 (Ad-p53) or wild type ade-
novirus (Ad-WT; as the negative control). The multiplicity of
infection (MOI) was deﬁned as the ratio of infectious virus particles
to cells. The titer of the virus was calculated using the standard is-
sue Culture Infectious Dose 50 (TCID50) following the manufac-
turer’s protocol (Ad Easy™ vector system; Qbiogene, Montreal,
PQ, Canada).
2.3. Construction of short hairpin RNAs (shRNAs) and analysis of
apoptotic cell death
Plasmid vector pcDNA6A:GFP::H1 (indicated as vector in the
text and ﬁgures) was designed to express green ﬂuorescent protein
(GFP) and shRNA under the cytomegalovirus promoter and H1 pro-
moter, respectively. The pcDNA6A:GFP::H1:shDUSP6 expressing
shDUSP6 (indicated as shDUSP6 in the text and ﬁgures) was gener-
ated by annealing the shDUSP6 oligonucleotides (generating over-
hang BglII and ClaI sites) and then ligating the annealed shDUSP6
oligonucleotides into BglII and ClaI sites of pcDNA6A:GFP:H1. The
oligonucleotides used for generation of shDUSP6 are listed in
Table 1. HCT116 parental cells and HCT116 p53/ cells were
transfected with either pcDNA6A:GFP::H1 vector or pcDNA6A:GFP::H1:shDUSP6 plasmids using Effectene transfection reagent
(Qiagen, Chatsworth, CA, USA) and transfected cells were selected
with blasticidin (10 lg/mL). The cells were subjected to treatment
with 50-FU (200 lg/mL) or Etoposide (100 lg/mL) for the indicated
times, and the cell death rates were monitored by XTT assay. The
data represented as mean ± standard deviation (S.D.; n = 3). The
knock-down efﬁciency was checked by western blotting.
2.4. DUSP6 over-expression
The full-length cDNA fragments of human DUSP6 ampliﬁed by
PCR were cloned into N-terminal ﬂag tagged PCR8/GW/Topo en-
try vector, and conﬁrmed by DNA sequencing analysis. The open
reading frame region of DUSP6 in the entry vector was subcloned
into the N-terminal GFP-tagged destination vector following the
Gateway Technology protocol (Invitrogen). The construction
was veriﬁed by automatic DNA sequencing. HCT116 parental cells
and HCT116 p53/ cells were transfected with either GFP:XB vec-
tor or GFP:DUSP6 using Effectene (Qiagen) and transfected cells
were selected with blasticidin (10 lg/mL). Transiently selected
cells were subjected to treatment with 50-FU (200 lg/mL) or Etopo-
side (100 lg/mL) for the indicated times.
2.5. Chromatin immunoprecipitation (ChIP) analysis
HCT116 parental (2  108) cells were seeded on 100 mm-diam-
eter dish (Nunc) and were treated with 50-FU (200 lg/mL) for indi-
cated the times on the following day. For cross-linking the bound
proteins to chromatin, the medium containing 1% formaldehyde
(Sigma–Aldrich) was added drop-wise directly into the dish, which
was then rotated gently at room temperature for 10 min. The
cross-linked cells were resuspended in swelling buffer (25 mM
HEPES pH 7.8, 1.5 mM MgCl2, 10 mM KCl, 0.1% NP-40, 1 mM dithi-
othreitol and freshly-added aforementioned protease inhibitor
cocktail). Following 10 min incubation on ice, nuclei were released
by homogenizing 20 times up-and-down. Nuclei were resuspended
in ChIP lysis buffer (50 mM HEPES–KOH pH 7.5, 140 mM NaCl,
1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate and the
aforementioned protease inhibitors) and sonicated to shear the
chromatins of average fragment size 500–1000 bp. The sheared
protein–DNA complexes were immunoprecipitated with anti-p53
antibody (Oncogene Science) and captured on protein A Sepharose
beads (GE Healthcare, Buckinghamshire, UK). After immunoprecip-
itation, the beads were washed three times with wash buffer (0.1%
SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris–Cl
pH 8.0) and once with ﬁnal wash buffer (0.1% SDS, 1% Triton
S. Piya et al. / FEBS Letters 586 (2012) 4233–4240 4235X-100, 2 mM EDTA, 500 mM NaCl, 20 mM Tris–Cl pH 8.0). Finally,
the chromatin complexes were eluted with elution buffer (1% SDS,
100 mM NaHCO3) and DNA–protein cross-linking was reversed by
addition of proteinase K and heating at 65 C overnight. The DNA
was puriﬁed by phenol extraction followed by ethanol precipita-
tion. PCR ampliﬁcation of the DUSP6 gene was performed using
the speciﬁc primers detailed in Table 1.
2.6. Statistical analysis
Values are presented as mean ± standard deviation. The paired
Student’s t-test was applied to determine whether the differences
between values were signiﬁcant (P < 0.05).
3. Results
3.1. p53 transactivates DUSP6 under genotoxic stresses
To identify novel targets that are transcriptionally activated by
p53, we performed DNA chip analysis with p53-expressing adeno-
virus-infected HCT116 cells using commercial oligonucleotide DNA
chips (Digital Genomics, Seoul, Korea). Several candidates includ-
ing DUSP6 of p53 target genes were identiﬁed (data not shown).
DUSP6 regulates proteins involved in both cell proliferation and
cell death [6,8]. Thus, we focused on whether DUSP6 is involved
in p53-mediated apoptosis. First, to verify the transactivation of
DUSP6 by p53, HCT116 p53 parental cells were infected with the
adenovirus expressing p53 (Ad p53) or the control adenovirus
(Ad control). RT-PCR analysis revealed the substantial increase of
DUSP6 mRNA in HCT116 p53 parental cells infected with Ad p53
compared to that in HCT116 p53 parental cells infected with Ad
control (Fig. 1A). Furthermore, treatment of HCT116 WT cells with
50-FU increased the endogenous p53 that results in the increased
expression of DUSP6 mRNA; however, HCT116 p53/ cells treated
with 50-FU showed no increase of DUSP6mRNA (Fig. 1B). To further
determine whether p53 was responsible for increasing the proteinA
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Fig. 1. p53 transactivates DUSP6 under genotoxic stresses. (A and B) HCT116 parental cel
p53 (Ad p53) for 6, 10 and 24 h. HCT116 parental cells and HCT116 p53/ cells (B) were
and GAPDH were analyzed by RT-PCR. (C and D) HCT116 parental cells and HCT116 p53
indicated times, and whole cell lysates were prepared using RIPA buffer. The whole cell
representative data were presented from three individual experiments.level of DUSP6 in response to different death stimuli, HCT116
parental cells and HCT116 p53/ cells were treated with 50-FU
and Etoposide. Indeed, treatment of 50-FU and Etoposide to
HCT116 parental cells, but not to HCT116 p53/ cells increased
the DUSP6 protein level while p53 protein level and p21 protein
(a best known p53 target gene) level were increased (Fig. 1C and
D). These results implicate that DUSP6 is a novel transcriptional
target of p53.
To probe for the potential p53 binding sites in the promoter re-
gion of DUSP6, computer analysis of the promoter region (about
2.5 kb from ATG translation start site) using MatInspector in Gen-
omatix (http://www.genomatix.de/) was performed. This analysis
revealed two putative binding sites at 1552/1585 and 2316/
2349 within 2.5 kb of the DUSP6 promoter region (Fig. 2A). These
putative binding sites contain the core region of the p53 binding
consensus motif. To investigate whether or not p53 could occupy
these putative binding sites in response to 50-FU, the chromatin
immunoprecipitation (ChIP) assay was performed. HCT116 paren-
tal cells were treated with 50-FU, and ChIP and PCR were performed
using anti-p53 antibody and primers comprising of 2404 to
2125 and 1625 to 1425, respectively (Fig. 2A). At 6 or 12 h
after 50-FU treatment, the putative p53 binding sites were occupied
by p53 (Fig. 2B), suggesting that these putative p53 binding sites
may be functional for DUSP6 expression in response to genotoxic
stresses like 50-FU.
3.2. DUSP6 plays a role in p53-mediated cell death induced by
genotoxic stresses
The transactivation of DUSP6 by p53 under genotoxic stress
suggests that DUSP6 may play a role in p53-mediated cell death.
To determine the role of DUSP6 in p53-mediated cell death, we
investigated the effects of the forced expression of DUSP6 on the
cell viability in response to 50-FU either in HCT116 parental cells
or in HCT116 p53/ cells. Ectopic expression of DUSP6 in
HCT116 parental cells or in HCT116 p53/ cells substantiallyD
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Fig. 2. DUSP6 promoter contains two putative p53 binding sites. (A) The schematic representation of two putative p53 binding sites in DUSP6 promoter region. (B) HCT116
cells were treated as indicated and were subjected to ChIP analysis. A p53-speciﬁc antibody was used to precipitate p53 bound to chromatin. The p53-associated DUSP6
promoter was PCR-ampliﬁed using the indicated primers. The representative data were presented from three individual experiments.
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Fig. 3. DUSP6 is a necessary factor for p53-mediated cell death. (A–C) HCT116 parental cells (A) and HCT116 p53/ cells (B) were transiently transfected with either control
vector or GFP fused DUSP6 expression construct (indicated as DUSP6). Twenty-four hours after transfection, cells were treated with 50-FU (200 lg/mL) for another 24 h. The
viability was measured by XTT assay (A and B) or caspase-3 activity was measured using colorimetric DEVD-pNA substrate (C). (D and E) HCT116 parental cells were
transfected with either vector control or shDUSP6 expression vector. The cells were treated with 50-FU (200 lg/mL) for 24 h. The viability was measured by XTT assay (D).
Immunoblottings using anti-DUSP6 and anti-actin antibodies (upper panel) or anti-GFP antibody (bottom panel) were carried out (E). Data were represented as
mean ± standard deviation (S.D.; n = 3) (Student’s t-test: ⁄P < 0.001.)
4236 S. Piya et al. / FEBS Letters 586 (2012) 4233–4240reduced the cell viability examined by XTT assays in response to 50-
FU (Fig. 3A and B). The reduction of cell viability by overexpression
of DUSP6 in HCT116 p53/ cells in response to 50-FU appeared to
be mainly due to apoptotic cell death because caspase-3 activity
was greatly enhanced by DUSP6 expression (Fig. 3C). Ectopic
expression of DUSP6 in HCT116 cells was conﬁrmed by Western
blot analysis (Fig. 3E)
To further conﬁrm the role of DUSP6 in p53-mediated cell
death, we examined the cell viability in HCT116 parental cellsexpressing DUSP6 shRNA (shDUSP6). The expression of DUSP6 ob-
served by Western blot analysis was signiﬁcantly reduced by
shDUSP6 in both 50-FU treated and untreated cells, but not by con-
trol vector (Fig. 3E). HCT116 parental cells expressing shDUSP6 dis-
played the increased cell viability induced by 50-FU (Fig. 3D),
Etoposide (Supplementary Fig. 1A) or TRAIL (Supplementary
Fig. 1B); however, HCT116 p53/ cells expressing shDUSP6
showed limited reduction of cell death in response to 50-FU, since
50-FU induces only limited, if any, death of HCT116 p53/ cells
S. Piya et al. / FEBS Letters 586 (2012) 4233–4240 4237(data not shown). These results indicate that the induction of
DUSP6 by p53 plays a critical role in genotoxic stresses and death
ligand-induced cell death.
3.3. Induction of DUSP6 by p53 in response to 50-FU is correlated with
dephosphorylation of ERK and the levels of the Bcl-2 family proteins
The magnitude and duration of ERK activity determine the cel-
lular proliferation and growth of tumor cells [21,22]. Since DUSP6
is a phosphatase speciﬁc for ERK dephosphorylation, we assumed
that the transactivation of DUSP6 by p53 might regulate the ERK
function in p53-mediated cell death. To show the functional link
between ERK dephosphorylation and DUSP6 induction by p53 in
p53-mediated cell death, DUSP6 induction and phosphorylation
status of ERK were observed in HCT116 parental cells and
HCT116 p53/ cells treated with 50-FU. As expected, in HCT116
parental cells, the ERK dephosphorylation was highly correlated
with p53 induction and subsequent induction of DUSP6 (Fig. 4A).
However, HCT116 p53/ cells showed only marginal increase of
ERK phosphorylation within 1–2 h after 50-FU treatment. Con-
versely, ERK was signiﬁcantly phosphorylated in HCT116 parental
cells expressing shDUSP6 in response to 50-FU (Fig. 4B). Since Bcl-2
has known to be phosphorylated by ERK [23], we examined the
phosphorylation status of Bcl-2 in HCT116 parental cells tran-
siently transfected with DUSP6 expression constructs. Control vec-
tor did affect a little or no changes of Bcl-2 phosphorylation status
at Thr 56 and Ser 70, whereas DUSP6 expression provoked signiﬁ-B
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ylation of Bcl-2 (Fig. 4C). Together, these results indicate that p53
transactivates DUSP6 that subsequently dephosphorylates ERK
when cells are challenged with genotoxic stresses.
Activated ERK phosphorylates Bad and Bcl-2 at serine residues
such that its pro-apoptotic function of Bad is masked, and Bcl-2
is protected from proteosomal degradation, leading to cell survival
[18,23]. Thus, we assumed that DUSP6-mediated dephosphoryla-
tion of ERK may inﬂuence the expression proﬁle of Bcl-2 family
proteins. In this context, to investigate the changes of expression
proﬁles of Bcl-2 family proteins, DUSP6 expression was suppressed
by introducing shDUSP into HCT116 parental cells or HCT116
p53/ cells. In both cells expressing shDUSP6, the expression lev-
els of Bcl-2 and Bcl-XL were increased, whereas that of Bad was de-
creased (Fig. 5A). On the contrary, when DUSP6 was overexpressed
in HCT116 parental cells or HCT116 p53/ cells, the expression
levels of Bcl-2 and Bcl-xL showed little decrease or no change in
both cells, whereas that of Bad was signiﬁcantly increased
(Fig. 5B). These results conﬁrm that DUSP6 determines the expres-
sion levels of Bcl-2 family proteins like Bcl-2, Bcl-xL, and Bad by
regulating ERK activity, and provides a functional signiﬁcance of
DUSP6 induction by p53 in p53-mediated apoptosis.
4. Discussion
Genotoxic stresses provoke cellular responses including cell
cycle arrest coupled with DNA repair or cell death. The huge linePhospho-Bcl-2 (Thr56)
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4238 S. Piya et al. / FEBS Letters 586 (2012) 4233–4240of evidence supports that p53 plays a key role in determining the
cell fate by transactivating distinct sets of target genes, leading
to cell cycle arrest or cell death [3,24]. Presently, we show that
p53 induces DUSP6, a key phosphotase for ERK, which enhances
cell death by modulating ERK phosphorylation and the expression
levels of Bcl-2 family proteins in response to genotoxic stresses.Cell membrane
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S. Piya et al. / FEBS Letters 586 (2012) 4233–4240 4239crucial role in p53-mediated cell death [33–37]. Also, it has re-
ported that DUSP1 and DUSP2 can be transactivated by glucose
deprivation or p53 during oxidative stress, leading to cell death
[34,38]. The present study adds DUSP6 to the list of p53-induced
target genes involved in inhibition of cell proliferation (Fig. 6).
Recent studies showed that E twenty six (Ets) 2 protein, the
well-known target of ERK signaling, activates DUSP6 transcription
by binding to the conserved binding site for Ets2 present in the up-
stream region of DUSP6 promoter in response to FGF [39,40] or in
response to PMA [41] or in the intron 1 of DUSP6 gene in response
to active ERK activity [42]. These results suggest a feedback loop
between DUSP6 and ERK and Ets2 in a way that DUSP6 transcrip-
tion is tightly regulated by Ets2 activity that is controlled by ERK
activity [42]. Ets1 also binds to DUSP6 promoter region to promote
DUSP6 transcription in lung cancer cells, and this elevation of
DUSP6 expression is abrogated by inactivation of ERK activity
[43]. This feedback regulatory loop can be also established be-
tween p53 and DUSP6 and Ets2. Our results indicate that p53 can
induce DUSP6 expression. As mentioned above, Ets2 activity is reg-
ulated by ERK that is inhibited by DUSP6. Ets2 can also transacti-
vate p53 by binding to Ets-binding sites in p53 promoter region,
and can provoke apoptosis in the thymus of Ets2 transgenic mice
or in Ets2-overexpressing HeLa cells. Ets2-induced apoptosis in
the thymus of Ets2-transgenic mice can be rescued by crossing
with p53-deﬁcient mice, revealing that p53 is a key mediator for
Ets2-induced apoptosis [44,45]. Thus, we suggest that Ets2 may
be an activator for both p53 and DUSP6, whereas p53 and DUSP6
may be an inhibitor for Ets2 through ERK inactivation. The
signaling axis of p53, DUSP6, ERK, and Ets2 may establish a feed-
back regulatory loop to determine the cell fate in response to
DNA damage.
ERK has shown as a key player to protect cells from apoptosis by
phosphorylating Bad and Bcl-2, resulting in the dissociation of Bad
from Bcl-XL and protection of Bcl-2 from proteosomal degradation
[18,19,46]. Our results showed that p53-dependent DUSP6 upreg-
ulation caused the dephosphorylation of ERK, affecting the expres-
sion levels of Bad, Bcl-2 and Bcl-xL. Indeed, the phosphorylation
status of Bcl-2 (Ser70) and the expression level of Bcl-2 protein
are signiﬁcantly decreased by DUSP6 expression (Figs. 4 and 5).
These results emphasize the role of p53 in modulating the expres-
sion levels of Bcl-2 family proteins by regulating DUSP6 expression
and its downstream substrate ERK. It is, also, of interesting to note
that DUSP6 is upregulated by tumor necrosis factor-alpha (TNF-a)
treatment, and cell death induced by TNF-a in HUVEC cells can be
completely blocked by a DUSP6 dominant negative mutant form
[23], indicating that modulation of DUSP6 expression could be a
key step to regulate cell death in some cells induced by not only
genotoxic stresses but also death ligands.
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